<!DOCTYPE html>
<html lang="en">
	<head>
		<meta charset="utf8">
		<meta name="viewport" content="width=device-width, initial-scale=1">
		<title>Risteys – PSORI_STRICT – detailed case counts by code</title>
		<style type="text/css">
body {
	font-family: sans-serif;
}
.bar-plot-full {
	width: 8rem;
	border-radius: 0.1rem;
	background-color: #f2f2f2;
}
.bar-plot-full div {
	background-color: #c7c7c7;
	height: 1rem;
	border-radius: 0.1rem;
}
		</style>
	</head>
	<body>

		<table>
			<tr>
				<th>Source</th>
				<th>Code</th>
				<th>Name</th>
				<th>Case count</th>
				<th>Share of cases (%)</th>
			</tr>

			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(319)_ICD10(L40)</td>
					<td>Adalimumab, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, sekukinumab and ustekinumab (skin psoriasis), Psoriasis</td>
					<td>307</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 49.2776886035313%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(319)_ICD10(L400)</td>
					<td>Adalimumab, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, sekukinumab and ustekinumab (skin psoriasis), Psoriasis vulgaris</td>
					<td>250</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 40.12841091492777%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(134)_ICD10(L400)</td>
					<td>General erythroderma, Psoriasis vulgaris</td>
					<td>148</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 23.756019261637242%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(319)_ICD10(L405)</td>
					<td>Adalimumab, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, sekukinumab and ustekinumab (skin psoriasis), Arthropathic psoriasis (M07.0-M07.3*, M09.0*)</td>
					<td>96</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 15.409309791332262%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(377)_ICD10(L40)</td>
					<td>Apremilast and dimethyl fumarate (psoriasis), Psoriasis</td>
					<td>61</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 9.791332263242374%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(134)_ICD9(NA)</td>
					<td>General erythroderma, Name not found</td>
					<td>46</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 7.3836276083467105%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(377)_ICD10(L405)</td>
					<td>Apremilast and dimethyl fumarate (psoriasis), Arthropathic psoriasis (M07.0-M07.3*, M09.0*)</td>
					<td>43</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 6.902086677367576%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(134)_ICD10(L26)</td>
					<td>General erythroderma, Exfoliative dermatitis</td>
					<td>26</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 4.173354735152488%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(377)_ICD10(L400)</td>
					<td>Apremilast and dimethyl fumarate (psoriasis), Psoriasis vulgaris</td>
					<td>21</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 3.3707865168539324%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(134)_ICD8(NA)</td>
					<td>General erythroderma, Name not found</td>
					<td>12</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 1.9261637239165328%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(134)_ICD9(6961A)</td>
					<td>General erythroderma, Psoriasis and similar disorders, Other psoriasis</td>
					<td>12</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 1.9261637239165328%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(319)_ICD10(L408)</td>
					<td>Adalimumab, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, sekukinumab and ustekinumab (skin psoriasis), Other psoriasis</td>
					<td>10</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 1.6051364365971106%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(134)_ICD10(NA)</td>
					<td>General erythroderma, Name not found</td>
					<td>5</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.8025682182985553%"></div>
						</div>
						
					</td>
				</tr>
			

		</table>

	</body>
</html>
